What You Should Listen for When Biogen Idec Inc. Reports Earnings

Biogen Idec is up over 100% in the last year, and reports. Here are some critical factors to stay focused on during the call.

Jan 24, 2014 at 6:25PM

Biogen Idec (NASDAQ:BIIB) will report earnings on Wednesday, January 29. The company's shares are up over 100% over the last twelve months, largely on the success of a new multiple sclerosis therapy that quickly elbowed past competition from both Sanofi (NYSE:SNY) and Novartis (NYSE:NVS). Highly effective new hemophilia therapies likely to be launched ahead of Novo Nordisk's (NYSE:NVO) also have investors excited.

Before getting caught up in posted figures versus expectations, it's always a good idea to make your own assessment of a company's long-term prospects. Let's take a closer look at a few key factors that we can listen for during the call. This way we can cut through the noise and measure the company's chances of continued success.

Insider selling
Before getting into critical factors that will affect Biogen's future profitability, we should address an issue that could cloud your judgement. You may have noticed news of insider selling at Biogen. This is true, but I don't think it's cause for alarm. As of January 23, 2014, five different directors, but not officers, have sold a combined 29,770 shares. The transactions represent just about 0.013% of total shares outstanding.

While it is certainly worth paying attention to insider transactions, viewed in context, I don't see any smoking gun here. At a recent price north of $310, the company's shares are trading at over 40 times trailing-twelve-month earnings. Generally in situations like these, without a real surprise to the upside, price gains made in anticipation of an earnings report are quickly wiped out. Given the odds, you can't blame insiders for taking some of their profits off the table beforehand.

Tecfidera launch
Insider transactions aside, we should take a good look at what to expect regarding Biogen's main sources of revenue. First up is the wildly successful oral multiple sclerosis therapy Tecfidera. Introduced in the beginning of April 2013, after six months it had already beat out Sanofi's Aubagio, and Novartis's Gilenya in terms of market share. According to Biogen Idec CEO, George Scangos, there are about 8,000-9,000 prescribing physicians for MS in the US. Six months after its launch, Tecfidera had been prescribed by over 5,000.

That's some amazing penetration, but eventually it needs to level off. With a price to earnings multiple of over 40 times trailing earnings any sign of Tecfidera slowing down in the US is likely to be magnified in the company's share price. If there are signs of a slowdown, listen closely to see if it is due to saturation or a lack of repeat prescriptions.

Avonex damage
This injectible MS treatment is still the company's largest source of revenue. When Biogen reported last, sales of oral Tecfidera hadn't eaten deeply into the injectible Avonex market. For Q3 2013, US sales of the drug dropped by just 1.1%. It's important to remember, that was just half a year into the launch. With another quarter past, there's a good chance that signs of increasing cannibalization will appear.

Hemophilia hold ups
Although Biogen derives the bulk of its revenue from MS therapies, the company is poised to break into the hemophilia space. This market is roughly estimated at $7 billion annually. The company has two therapies currently under review at the FDA: Eloctate for hemophilia A, and Alprolix for hemophilia B.

While the condition is treatable, there is a significant lack of extended duration therapies. Hemophilia patients often require frequent intravenous infusions to treat the disease. Both of Biogen's therapies under review have been shown to effectively reduce the number of infusions required. In an increasingly austere reimbursement environment, this is just the sort of cost cutting therapy that has a solid chance of gaining traction, if it wins approval.

If Eloctate is approved, it won't be the only new hemophilia A treatment on the market for long. Last October, the FDA approved Novoeight from Novo Nordisk for treatment of hemophilia A patients. Biogen's therapy couldn't beat Novo's in the race to approval, but Eloctate might hit the US market first. Novo is awaiting the expiration of existing patents, before launching Novoeight shortly after April 2015.

Biologics license applications for Biogen's hemophilia therapies should have resulted in decisions already, but there have been delays with the review process. Last October, the FDA raised concerns over the validation of steps in Eloctate's manufacturing process, which could hold up the approval process. In December of last year, the regulator imposed a similar delay for Alprolix.

Of course, manufacturing process issues could delay approvals well beyond the extension period. When Biogen last reported earnings, management did not provide a time frame for Eloctate due to active discussions with the agency. More recently, during the 2014 J.P. Morgan Healthcare Conference, Scangos said he was expecting an Eloctate decision about halfway through the year, and Alprolix in the second quarter. It was just a brief statement without much background, but I'll be listening closely for more details about the delays during the upcoming earnings call.

Bring on the call
Now that you have a few key items to listen for, you should be prepared to quickly assess Biogen's growth potential, without getting overwhelmed by the noise. Given the company's high valuation, price movement after the call is almost certain. If you've been holding onto this rocket, some confidence in your own judgement could be keep you from making a decision you'll regret.

More great biotech opportunities
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers